Drug intelligence / Profile preview

Oxy16

Development stage: Preclinical
Lead developer: MAX BioPharma
Modality: Small Molecules
Administration: Oral

Overview

Oxy16 is a naturally occurring oxysterol derivative developed by MAX BioPharma for the treatment of pancreatic cancer. As a dual-action small molecule, Oxy16 functions as an agonist of the Liver X Receptor (LXR) and an inhibitor of paracrine Hedgehog (Hh) signaling. This mechanism is intended to modulate the tumor microenvironment and inhibit the growth of pancreatic ductal adenocarcinoma (PDAC) by disrupting the signaling between tumor cells and the surrounding stroma. Oxy16 is currently in the preclinical stage of development.

Other names: Oxy16Oxy-16Oxy 16

Targets

NR1H3 (Liver X receptor beta)

Beyond the preview

Go deeper on Oxy16.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxy16.

Explore the full profile